PTPRE

Across TCGA pan-cancer cohorts, PTPRE mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PTPRE data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PTPRE mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PTPRE expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, HNSC, and PDAC are the cancer types where PTPRE mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	0.915	0.624	.001	26	view →
HNSC	DFS	Tertile	III,IV	1.000	0.907	.016	14	view →
PDAC	OS	Tertile	II,III,IV	0.698	0.936	.013	10	view →
CCRCC	DFS	Median	II,III,IV	0.810	0.592	.013	7	view →
COAD	DFS	Median	III,IV	0.893	1.000	.033	6	view →
GBM	OS	Tertile	All	0.872	0.704	.027	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PTPRE–LUAD (OS)

Open the LUAD breakdown →